NYMC Faculty Publications

High-Risk Pulmonary Hypertension Does Not Worsen Outcomes in Heart Transplantation

Wojciech Rzechorzek, Departments of Cardiology, New York Medical College/Westchester Medical Center, Valhalla, New York.
Subo Dey, Departments of Internal Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York. Electronic address: subo.dey@wmchealth.org.
Avisha Shah, Departments of Internal Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York.
Liana Michaud, Departments of Internal Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York.
Dennis Boyle, Departments of Internal Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York.
Areen Pitaktong, Departments of Internal Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York.
Avi Levine, Departments of Cardiology, New York Medical College/Westchester Medical Center, Valhalla, New York.Follow
Stephen Pan, Departments of Cardiology, New York Medical College/Westchester Medical Center, Valhalla, New York.Follow
Suguru Ohira, Departments of Cardiothoracic Surgery, New York Medical College/Westchester Medical Center, Valhalla, New York.Follow
Alan Gass, Departments of Cardiothoracic Surgery, New York Medical College/Westchester Medical Center, Valhalla, New York.Follow
Masashi Kai, Departments of Cardiothoracic Surgery, New York Medical College/Westchester Medical Center, Valhalla, New York.Follow
Gregg M. Lanier, Departments of Cardiology, New York Medical College/Westchester Medical Center, Valhalla, New York.Follow

Author Type(s)

Resident/Fellow, Faculty

DOI

10.1016/j.amjcard.2023.07.009

Journal Title

The American Journal of Cardiology

First Page

290

Last Page

297

Document Type

Article

Publication Date

10-15-2023

Department

Medicine

Second Department

Surgery

Abstract

Pulmonary hypertension (PH) is a relative contraindication to heart transplantation (HT). Multiple studies showed increased mortality in patients with PH. Advances in care may have led to improved outcomes in the modern era. We analyzed patients who underwent HT at our institution between 2014 and 2018. We divided patients into 2 groups based on the presence of high-risk PH defined as either pulmonary vascular resistance >3 Wood units or transpulmonary gradient >15 mm Hg. The primary outcome was survival. Secondary outcomes were post-HT morbidity and changes in hemodynamics. Subsequently, we analyzed national trends of single organ HT recipients with a high-risk PH between 1994 and 2018 from the United Network for Organ Sharing registry. Of 98 patients who underwent HT at our center, 32% had PH. In patients without and with PH, the survival was 100% at 30 days, 87%, and 81% at 3 years (p = 0.96). In both groups, pulmonary vascular resistance and trans-pulmonary gradient decreased after HT. Nationwide data revealed 30-day survival without and with PH at 97% and 98% (p = 0.47) and 3-year survival at 86% and 87% (p = 0.84), respectively, in 2018. The proportion of recipients with PH decreased from 25% in 1994 to 19% in 2018. Recipients of HT with and without high-risk PH had similar early and late mortality in a single-center and nationwide analysis. PH improved immediately after transplant. The United Network for Organ Sharing registry analysis demonstrates continued improvement in survival in patients with PH in the modern era, whereas the relative percentage of recipients with PH decreased over time.

Link to Full Text

Share

COinS